ELANCO ANIMAL HEALTH INC
ELANNYSETrading Snapshot
- Day Range
- $22.57 β $22.92
- 52-Week Range
- $19.40 β $27.98
- Volume (shares)
- 479,686
- Avg Volume (shares)
- β
- Shares Outstanding
- 499.6M
- Next Earnings
- 2026-11-06
Fundamentals Snapshot
- Annual Revenue
- $4.71B
- Last Q Revenue
- $1.37B
- P/E Ratio
- β
- P/S Ratio
- 2.3x
- EPS (TTM)
- $-0.42
- Dividend Yield
- β
- Dilution (1yr)
- +0.5%
ELANCO ANIMAL HEALTH INC
ELANAbout ELANCO ANIMAL HEALTH INC
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.